After two reported incidents and early system substitutes were linked to an electrical damage in some older Boston Scientific pacemakers, the U.S. Food and Drug Administration issued an essential health alert.
Boston Scientific said about 13 % of devices from its Accolade community of pacemakers built before September 2018 experience an increased possibility to start” health mode”, a non-programmable backup moving that may not provide optimal assistance of a patient’s respiratory condition, the company said in its own , serious notice , to doctors. The system has about four years or less of battery life left, and this is the result of an “unanticipated focus of lithium salts resulting from variability in battery assembly techniques,” according to the manufacturer.
In its call released on Monday, the FDA stated that Boston Scientific and the FDA are “working together to assess the potential danger of this problem in all Accolade defibrillator devices and recommend further mitigation strategies as needed.”
The system concern was linked to a “manufacturing problem,” according to the FDA. There have been 697 confirmed problems in the almost 203, 000 affected products in the market.
Because of the possibility that these devices shift to Safety Mode according to an increased interior power impedance, Boston Scientific stated in a statement that it freely issued an expert involving the subset of pacemakers.
This behavior may later in the life of a system and may necessitate the alternative of some patients. No implants are still available for prosthetic use in the expert population, and early device replacement has been the most common clinical outcome, according to the company.
The email was sent to health care providers by Boston Scientific, which has roughly 9,400 people in Minnesota.
Typically, a device system is designed to supply adequate power capacity to support system operations for three months, the company’s notice said. The supply battery power for a system that enters health method due to high battery impedance may not be sufficient to support three months of operation. It should be scheduled for replacement shortly thereafter or immediately for patients who are at risk of harm from Safety Mode parameters, according to the company in its notice.
Boston Scientific stated in the letter that it is working on a software update for the affected devices that will detect and display an alert when a high impedance battery state occurs. It added that the modification of processing methods has reduced the variability of lithium salt concentrations and increased battery performance in pacemakers.
According to the company,” Physicians following patients who have devices in the advisory population have been given recommendations intended to reduce the risk of the behavior” and will contact them directly if a separate appointment is needed to examine the device,” the statement read.
The affected devices include: Accolade, Proponent, Essentio, and Altrua 2 dual-chamber standard life and DR extended life pacemakers, as well as Visionist and Valitude cardiac resynchronization therapy pacemakers. The organization recommended that doctors perform emergent replacement procedures for patients who were at risk of harm.
___
© 2024 The Minnesota Star Tribune
Distributed by , Tribune Content Agency, LLC
